Hims & Hers Health (HIMS) Stock Price, Chart, Company Profile & AI Analysis

Key Takeaways

• HIMS shares surged approximately 27.9% over the past 30 days, climbing from $27.76 on June 1 to $35.50 as of July 1, 2026.
• The rally was fueled by Barclays raising its price target to $39, growing optimism around the Novo Nordisk partnership, and the completed Eucalyptus acquisition.
• Over the full quarter, the stock has soared roughly 78.9%, recovering sharply from a post-earnings sell-off in mid-May that briefly pushed shares below $22.
• Employer plans to drop GLP-1 coverage in 2027 are seen as a potential tailwind, pushing more patients toward cash-pay telehealth platforms like Hims & Hers.
• An upcoming FDA advisory committee meeting on peptide compounding in late July represents a key regulatory catalyst that could shape the company's next growth phase.

Hims & Hers Health (HIMS) Company Overview and Market Position

Hims & Hers Health, Inc. operates a consumer-first telehealth platform that connects users with licensed healthcare professionals across the United States, the United Kingdom, Canada, and several European markets. The company offers an integrated digital experience spanning men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens, mental health support, and weight management. Its weight-loss business, which accounts for roughly one-third of revenue, has become a central growth driver following the company's March 2026 partnership with Novo Nordisk to offer branded GLP-1 medications. With 2.6 million subscribers as of the first quarter and a rapidly expanding international footprint, Hims & Hers has positioned itself as one of the largest direct-to-consumer telehealth platforms in the weight-loss market.

Hims & Hers Health (HIMS) Stock Price Performance: Last 30 Days vs. Quarter

HIMS shares have delivered a powerful 30-day rally, rising from a closing price of $27.76 on June 1, 2026, to $35.50 as of July 1, 2026—a gain of approximately 27.9%. The move marks a decisive breakout above the $30 resistance level that had capped the stock in April and triggered a multi-week sell-off. Zooming out to the quarterly view, the performance is even more striking. From a close of $19.84 on April 1, the stock has surged roughly 78.9%, recovering all losses from the sharp post-earnings decline in mid-May, when shares briefly traded below $22 after the company reported a significant first-quarter earnings miss. The quarterly trend reflects a broader narrative shift from regulatory uncertainty toward renewed conviction in the company's growth trajectory.

What Drove HIMS Stock Price in the Last 30 Days

Several catalysts converged to drive the 30-day surge in HIMS shares. The most prominent was a bullish research note from Barclays on June 17, in which the firm raised its price target from $29 to $39 and reiterated an Overweight rating. Barclays cited alternative data showing a "clear inflection post-Novo" since the partnership was announced in March, along with expectations for a significant acceleration in revenue and EBITDA during the second half of 2026. The upgrade helped propel the stock above the psychologically important $30 level.

Additionally, a Reuters report on June 25 highlighted that Novo Nordisk's U.S. operations executive described Hims & Hers as one of the drugmaker's most "voluminous" telehealth partners, reinforcing confidence in the commercial traction of the branded GLP-1 offering. Investor sentiment also benefited from reports that approximately 10% of employers currently covering GLP-1 drugs for weight loss plan to drop coverage in 2027, a shift that could channel more patients into cash-pay platforms like Hims. The company's completion of the Eucalyptus acquisition in June further expanded its international reach, adding an estimated $450 million in annual revenue run-rate across Australia, the U.K., and Canada. A director's open-market purchase of 48,400 shares in late May at approximately $24.24 also signaled insider confidence during the early stages of the recovery.

What Drove HIMS Stock Performance Over the Last Quarter

The quarterly performance tells a story of sharp volatility and a powerful rebound. The period began with the stock trading near $20, still recovering from the regulatory overhang that had plagued the telehealth sector since late 2025. A major inflection point arrived in mid-April, when shares spiked from around $21 to above $31 in a matter of days, driven by enthusiasm around the newly announced Novo Nordisk partnership and raised FY2026 guidance. However, the rally proved fragile. On May 11, Hims reported first-quarter results that badly missed expectations—EPS of -$0.40 versus consensus estimates of $0.04, and revenue of $608.1 million against expectations of $616.84 million. The stock plunged, eventually bottoming near $22 by May 18-19.

What followed was a methodical recovery built on improving fundamentals and a series of positive developments. The Eucalyptus acquisition, announced in late May, gave investors a tangible international growth story. The Barclays upgrade in mid-June validated the thesis that the Novo partnership was gaining real commercial momentum. By quarter-end, the stock had not only recovered its post-earnings losses but had broken out to levels not seen since April, reflecting a market willing to look past near-term margin pressure toward the longer-term opportunity in weight-loss, peptides, and global expansion.

Trending AI Robots

In a market environment where rapid price swings and sector rotations can challenge even experienced investors, AI-driven trading tools have gained significant traction. Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots from a universe of hundreds that trade thousands of tickers. These bots employ diverse strategies, timeframes, and performance metrics, allowing traders to identify approaches aligned with their own risk tolerance and market outlook. Only the most relevant and consistently performing bots appear in this section, providing a streamlined way to explore algorithmic trading without sifting through an overwhelming number of options. For those seeking data-driven insights in volatile markets, the Trending AI Robots page serves as a practical starting point.

HIMS Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several factors will be critical in determining whether HIMS can sustain its recent momentum. The Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24 will review whether seven peptides should be added to the FDA's 503A Bulk List—a decision that could open a significant new product category for Hims beyond 2027. Second-quarter earnings, expected in early August, will provide the first clear read on how many new subscribers the Novo Nordisk partnership has attracted and whether the weight-loss portfolio is meeting internal targets. Analysts will also scrutinize gross margin trends, which came under pressure in Q1, and the integration progress of the Eucalyptus acquisition. On the macro front, any changes to FDA guidance on telehealth prescribing of GLP-1 medications or shifts in employer insurance coverage patterns could materially impact the company's addressable market. With elevated short interest reported at over 28%, the stock may also remain susceptible to sharp moves in either direction based on news flow and earnings results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations